Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for proton pump inhibitors
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
No Association Between ProtonPumpInhibitor Use and Risk of Alzheimer's Disease The objective of the study was to investigate whether protonpumpinhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD).A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case
Gastric Ulcer Complications after the Introduction of ProtonPumpInhibitors into Clinical Routine: 20-Year Experience The aim of this study was to analyze the admissions and the management of peptic ulcer disease (PUD) in a tertiary care surgical center.We evaluated the medical records of all patients admitted to the University Hospital of Tübingen, Germany, for treatment of PUD during 1989-2008. Patients were included into the study if the diagnosis was verified endoscopically or surgically (...) . Annual number of admissions, length of hospitalization, mortality rate, age, rate of non-steroidal anti-inflammatory drugs (NSAIDs) and protonpumpinhibitor (PPI) medication, rate of Helicobacter pylori infection, and complications of PUD and surgery performed were recorded. Data were analyzed by descriptive analyses, Pearson's chi-square test, and regression analysis.This study included 614 admissions. The number of annual admissions (31 ± 12), the length of hospitalization (9 ± 3 days
Deprescribing protonpumpinhibitors 354 Canadian Family Physician • Le Médecin de famille canadien | Vol 63: may • mai 2017 Clinical Practice Guidelines Deprescribing protonpumpinhibitors Evidence-based clinical practice guideline Barbara Farrell PharmD ACPR FCSHP Kevin Pottie MD CCFP MClSc FCFP Wade Thompson Taline Boghossian ACPR Lisa Pizzola MSc Farah Joy Rashid ACPR Carlos Rojas-Fernandez PharmD Kate Walsh ACPR Vivian Welch PhD Paul Moayyedi MB ChB PhD MPH Abstract Objective To develop (...) an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop protonpumpinhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process
Deprescribing versus continuation of chronic protonpumpinhibitor use in adults. Protonpumpinhibitors (PPIs) are a class of medications that reduce acid secretion and are used for treating many conditions such as gastroesophageal reflux disease (GERD), dyspepsia, reflux esophagitis, peptic ulcer disease, and hypersecretory conditions (e.g. Zollinger-Ellison syndrome), and as part of the eradication therapy for Helicobacter pylori bacteria. However, approximately 25% to 70% of people
Clopidogrel and ProtonPumpInhibitor Use: A Review of the Evidence on Safety Clopidogrel and ProtonPumpInhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and ProtonPumpInhibitor Use: A Review of the Evidence on Safety Clopidogrel and ProtonPumpInhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drug Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of protonpumpinhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. The evidence suggests that there are still some serious safety risks associated with the use of protonpumpinhibitors (PPIs) with clopidogrel antiplatelet
Protonpumpinhibitors for functional dyspepsia. Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including protonpumpinhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially (...) in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.To determine the efficacy of protonpumpinhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia.We searched in the following
[Optimal long-term use of protonpumpinhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of protonpumpinhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of protonpumpinhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of protonpumpinhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIs is unwarranted in many cases. • It will take more than clinical tools and training
ProtonPumpInhibitors and Kidney Diseaseâ€”GI Upset for the Nephrologist? Widely regarded as safe and effective, protonpumpinhibitors (PPIs) are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute
ProtonPumpInhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) June 26, 2017 ProtonPumpInhibitors (PPIs): Is Perpetual Prescribing Inevitable? Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success? Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs. Evidence: • Clustered randomized
Community acquired pneumonia incidence before and after protonpumpinhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of protonpumpinhibitor (PPI) and assess whether unmeasured confounding explains this association.Design Cohort study and self controlled case series.Setting Clinical Practice Research Datalink (1990 to 2013) in UK.Participants Adult patients with a new prescription for a PPI individually
A systematic review of the comparative effectiveness of protonpumpinhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of protonpumpinhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of protonpumpinhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of protonpumpinhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were
Meta-analysis of the efficacy of protonpumpinhibitors for the symptoms of laryngopharyngeal reflux. The objective of this study was to perform a systematic review and meta-analysis to assess the effectiveness of protonpumpinhibitors (PPI) for reflux disease in adult patients with laryngopharyngeal symptoms. A comprehensive search of Cochrane Library, EMBASE, Ovid EBM Reviews, and PubMed was performed for English-language literature about laryngopharyngeal reflux (LPR), in September 2014
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with protonpumpinhibitors Polymorphisms in genes encoding drug metabolizing enzymes may lead to varied enzyme activity and inter-individual variability in drug efficacy and/or toxicity. Since CYP2C19 and CYP3A4 genes code for enzymes involved in metabolizing wide variety of drugs including protonpumpinhibitors, we sought to identify polymorphisms in these genes in order to study their impact (...) on drug metabolism in subjects.DNA was isolated from healthy individuals including tribals and genotyped for 11 single nucleotide polymorphisms in CYP2C19 and 6 polymorphisms in CYP3A4. Individuals were categorized into different phenotypes based on their drug metabolizing genotype. Volunteers from each group were administered protonpumpinhibitors (Esomeprazole, Pantoprazole; 40 mg/day) for 5 days followed by pharmacokinetic studies and measurement of intra-gastric pH.Of the 17 polymorphisms studied
[Comment on â€œIndividual ProtonPumpInhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Reviewâ€]. 27218125 2016 08 24 2018 12 02 2174-2030 35 1 2016 Jan Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology Rev Port Cardiol [Comment on “Individual ProtonPumpInhibitors and Outcomes in Patients (...) With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review”]. 71-2 Mimoso Jorge J por Journal Article Comment Comentário a «Efeitos dos inibidores da bomba de protões em doentes com doença arterial coronária sob dupla antiagregação plaquetar: uma revisão sistemática» . Portugal Rev Port Cardiol 8710716 0870-2551 0 Platelet Aggregation Inhibitors 0 ProtonPumpInhibitors OM90ZUW7M1 Ticlopidine R16CO5Y76E Aspirin IM J Am Heart Assoc. 2015 Nov;4(11). pii: e002245. doi: 10.1161/JAHA
Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with ProtonPumpInhibitors Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by protonpumpinhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify
Pre-Endoscopic Intravenous ProtonPumpInhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous ProtonPumpInhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Pre-Endoscopic Intravenous ProtonPumpInhibitors for Emergency Department (...) Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous ProtonPumpInhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: February 5, 2016 Project Number: RC0740-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness
Concern for Myocardial Infarction Risk Associated with ProtonPumpInhibitor Use in Patients With No Underlying Cardiovascular Disease "Concern for Myocardial Infarction Risk Associated with ProtonPump Inh" by Natasha K. Ludwig < > > > > > Title Author Date of Graduation Fall 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Proton (...) . The purpose of this review is to explore if PPI use is associated with an increased MI risk in patients with no underlying cardiovascular disease. Methods: An exhausted search of available medical literature was performed using MEDLINE-Ovid, MEDLINE-Pubmed, Web of Science, and CINAHL using the keywords protonpumpinhibitors, myocardial infarction, and epidemiology. Relevant articles were assessed for validity using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system
Are We Overusing ProtonPumpInhibitors? Are We Overusing ProtonPumpInhibitors? – Clinical Correlations Search Are We Overusing ProtonPumpInhibitors? November 13, 2015 7 min read . PPIs are the most potent inhibitors of gastric secretion and are used to treat common upper gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. The effectiveness of PPIs and their perceived low toxicity profile have led to their popularity and even inappropriate (...) , Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-319. 7. U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of ProtonPumpInhibitor drugs (PPIs). Published March 2, 2011. Accessed 8. Perazella MA. Protonpumpinhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553-556. 9. Khalili H, Huang ES, Jacobson